Background: Platinum-resistant ovarian cancer (PROC) constitutes a therapeutic dilemma with limited efficacy from traditional cytotoxic agents. Based on prior data suggesting that scheduling alterations of platinum would increase activity, the aim of the present study was to assess the potential therapeutic benefit of phenoxodiol (PXD), a novel biomodulator shown to have chemoresistance reversing potential, when combined with weekly AUC2-carboplatin in PROC patients.
Dose-dense weekly application of either cisplatin [6, 7] or carboplatin [8] [9] [10] [11] showed significant activity in phase II trials in PROC, although there are no randomized data in this setting. The significant activity demonstrated in these studies of weekly schedule platinum was the basis for the rationale of this study, that of utilizing a sensitizer of platinum sensitivity, together with a potentially favorable platinum schedule. Phenoxodiol (PXD) is a sterically modified version of the naturally occurring plant isoflavone, genistein. Exposure of human cancer cells to PXD upregulates proapoptotic ceramide lipid levels with a concomitant reduction in sphingosine-1-phosphate leading to AKT inhibition [12, 13] . PXD induces mitotic arrest in G1 phase of the cell cycle due to p53-independent upregulation of p21 Waf1/CIP1, inducing apoptosis through inhibition of antiapoptotic proteins [13] .
PXD has additive and synergistic interactions with cytotoxics including cisplatin, carboplatin, gemcitabine, paclitaxel, docetaxel and topotecan in a wide range of cancer cells, including human ovarian cancer [12, 14] . In a phase II study of intravenous PXD combined with either cisplatin or paclitaxel in PROC, stable disease rates of more than 55% and overall response rates (ORRs) as high as 19% were demonstrated with good tolerance [15] . No phase II efficacy studies were conducted with oral PXD before the initiation of ovarian tumor response (OVATURE). However, phase I/II safety and pharmacokinetic studies with oral PXD suggested that the drug was immediately conjugated (glucuronidated) to an inactive metabolite and animal models demonstrated that this conjugation and inactivation was reversed within tumors, providing a tumor targeting strategy. This was the primary rationale to proceed with OVATURE (Clinicaltrials.gov identifier NCT00382811) [13, 15] .
Based on the promising phase II results in PROC, this trial was designed to confirm a clinically important interaction of PXD and carboplatin in this patient population.
patients and methods
patients PROC patients with histologically confirmed nonmucinous ovarian, fallopian tube or primary peritoneal carcinoma of epithelial origin were eligible for the study if they fulfilled all of the following criteria: patients must have received at least one line of platinum-based chemotherapy (cisplatin or carboplatin) for recurrence having responded to first-line therapy previously; platinum-resistant recurrence was defined as RECIST measurable disease relapse within 6 months of completing second or subsequent course of platinum therapy at the time of enrollment, taken from the last day of platinum therapy. Inclusion criteria included measurable disease (≥10 mm by spiral CT and ≥20 mm by conventional CT), estimated survival of at least 3 months, Karnofsky performance score (KPS) ≥60 and normal biochemistry/ hematology.
The study was conducted in accordance with Good Clinical Practice 
study design
The primary objective of this study was to compare the PFS of (i) daily oral PXD in combination with weekly carboplatin with (ii) daily oral placebo in combination with weekly carboplatin in patients with PROC.
Secondary objectives included comparisons of ORRs and duration of response, overall survival (OS) and quality of life (QoL). Weekly carboplatin was to be delivered at the maximum single-agent weekly dose of AUC2. Clinical characteristics are described in Figure 1 . We also evaluated the disease control rate (any response achieved other than progressive disease).
treatment and follow-up procedures
Patients were randomized, 1 : 1 to either (i) PXD + carboplatin or (ii) placebo + carboplatin. PXD and the placebo were taken daily every 8 h.
Carboplatin. Carboplatin was given weekly over 1 h, dosed at AUC2, based on the Calvert and Cockroft-Gault formulae.
Phenoxodiol. PXD was administered orally, 400 mg 8 hourly continuously, unless body weight was >100 kg where a 50% increase to 600 mg was applied, on an empty stomach at least 30 min before eating. No precautions or preventative therapies were required as oral PXD has been shown to be tolerable.
A treatment cycle was defined as 28 days. Treatment with both carboplatin and PXD or placebo was to be continued until disease progression, doselimiting toxicity or patient withdrawal. Dose adjustments or interruptions of carboplatin were undertaken based on toxicity using standard criteria for both drugs.
Patients were evaluated weekly for toxicity. Efficacy assessments (CT) were carried out 8-weekly. CA125 levels were measured biweekly. QoL instruments (FACT-O and FACT-BRM) were administered 8-weekly.
end points and sample size
Clinical response and progression were assessed according to RECIST criteria [16] , by an independent Tumor Response Evaluation Committee (TREC) rather than investigators. CA125 response and progression was assessed according to the GCIG criteria [17] . PFS (the primary end point) was measured from the day of randomization to the day of documented disease progression or death while OS was measured from the day of randomization to death. Stable disease was defined as any response between a partial response and tumor progression.
Toxicity was assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 (CTCAE v3).
QoL was measured by the validated FACT-O and FACT-BRM and was assessed at screening and the end of every second cycle.
statistical analysis
The study was originally designed to detect an improvement in median PFS from ∼5 months in the control group to ∼8 months in the experimental group, corresponding to a PFS hazard ratio of 0.625. Based on projected recruitment duration of 36 months a sample size of 340 patients was planned. A single interim analysis was pre-specified at ∼50% of the planned PFS events (∼95 of 170), utilizing O'Brien-Fleming stopping boundaries at an α level of 0.005. The final analysis was planned at a two-sided α of 0.048. All efficacy analyses were conducted on all randomized patients (intention-totreat population) while all toxicity analyses were conducted on the safety population defined as all randomized patients who received at least one dose of protocol-defined therapy. Patients who discontinued protocol-defined therapy before disease progression or death were censored at (i) the last date of tumor evaluation for the PFS analysis and (ii) the last date of known contact for the OS analysis.
Owing to early discontinuation of the study at 142 patients the statistical plan was revised. This number of patients, accrued over the 28 months that the study recruited would have been sufficient to detect a PFS difference at a two-sided 5% significance with a hazards ratio of 0.56 at the time of immediate analysis at trial cessation, with 94 events occurring, similar to the interim analysis. The revised final analysis (included in this manuscript) for the primary (PFS) and secondary (OS) end points, utilized this same number of patients, to be conducted when the last patient had died or completed at least 18 months in the study. Delivered carboplatin dose intensity (DI) (AUC/week) and delivered cumulative carboplatin dose (AUC) were calculated for each patient in the trial in order to determine whether PXD was affecting carboplatin delivery.
results patients
Based on an observed recruitment velocity far below that originally projected, due to changing patterns of standard of care and the stringency of inclusion/exclusion criteria of this trial, the IDMC felt that that timely completion of recruitment to the trial (n = 340) was unlikely to be feasible and therefore recruitment was discontinued on 14 April 2009 at 142 patients ). An amended statistical analysis plan was developed and a revised final analysis was planned at discontinuation of the trial (see Statistical analysis). Patients were randomized at 49 sites; 72 patients to placebo + carboplatin and 70 to PXD + carboplatin (Figure 1 ). At the time of the interim PFS analysis, 110 patients had progressed or died without evidence of progression and 32 were censored (19 in the control group and 13 in the PDX group). At the time of the final OS analysis, 118 patients had died and 24 were censored (13 in the control group and 11 in the PDX group). The median age was 57.5 years (range: 39-78 years) in the PXD/Carboplatin group and 59.0 years (range: 37-82 years) in the placebo/carboplatin group. Both arms were well balanced regarding important baseline characteristics, stratification factors, duration of study treatments, number of treatment cycles and other patient characteristics (Table 1) . Withdrawals are summarized by subgroup in Table 2 . There were similar numbers of patients in each treatment group attending each visit and having evaluable tumor responses. The duration of study treatments and number of treatment cycles were similar between the two treatment groups and there were no obvious differences seen within any of the subgroups. Prior treatment and platinum-free interval were well balanced between the arms and are presented by cohort and overall in supplementary Table S3 , available at Annals of Oncology online. All patients had received prior carboplatin or cisplatin.
delivered dose intensity/cumulative dose of carboplatin
The mean delivered carboplatin DI in the carboplatin + placebo arm was AUC 1.81/week (SD = 0.252) compared with AUC 1.72/week (SD = 0.31) for the carboplatin + PXD arm, which was not significant (unpaired t-test, P = 0.0745). The mean delivered carboplatin cumulative dose (CD) in the carboplatin + placebo arm was AUC 25.58 (SD = 22.58), compared with AUC 24.71 (SD = 20.57) for the carboplatin + PXD arm, which was again not significant (unpaired t-test, P = 0.816). Confirmed ORR was 1.4% in the placebo group versus 0% in the PDX group while stable disease was 52.8% and 51.4%, respectively, in the ITT population. ORRs (ITT population) are presented in detail in supplementary Table S4 , available at Annals of Oncology online.
CA125 outcomes. There was no evidence of a CA125 response, defined by a sustained fall of at least 50% in CA125 for patients who had a valid baseline measure of CA125 in any of the subgroups. Also there was no indication of a treatment effect in progressive disease as defined by two consecutive values at least 7 days apart ≥2× ULN in any of the subgroups. Table S1 , available at Annals of Oncology online summarizes the dose modification in both arms of the trial. A total of 1362 and 1374 AEs occurred post-treatment in the PXD + carboplatin and placebo + carboplatin groups, respectively. Five hundred eighteen AEs were deemed possibly, probably or definitely related to the PXD + carboplatin combination and 472 to the placebo + carboplatin combination, the majority being mild (G-1). The commonest AEs were neutropenia, thrombocytopenia and diarrhea. There were six SAEs that resulted in death and were the result of progressive disease. No treatment related G-3 or 4 renal or hepatic toxic changes were recorded (supplementary Table S2 , available at Annals of Oncology online).
quality of life
QoL was summarized by cycle. Approximately 50% of patients completed QoL questionnaires at cycle 2 for each treatment group with the numbers of questionnaires completed at subsequent cycles reducing significantly. There were no significant differences between the two treatment groups for the change in scores over time (ITT: P = 0.4, PP: P = 0.2).
discussion
This report summarizes the first clinical phase III trial, to our knowledge, to study the impact of fractionating the schedule of carboplatin in a weekly AUC2 regimen as a chemotherapeutic backbone in patients with PROC. The study used weekly carboplatin to help overcome platinum resistance and combined carboplatin with phenoxidol to see if the activity of carboplatin was augmented by this chemosensitizer. The impact of weekly dosescheduling of carboplatin has not previously been evaluated in PROC, but was considered justifiable based on promising data from weekly scheduled paclitaxel in combination with carboplatin delivering enhanced activity in PROC [18] [19] [20] and activity of weekly carboplatin AUC2 in platinum pretreated patients [6, 7, [9] [10] [11] Despite other promising preclinical and early clinical results of PXD against epithelial cancers [21, 22] , this study failed to demonstrate activity for weekly carboplatin AUC2 in patients with PROC as judged by CA125 and RECIST response parameters. The addition of oral PXD did not demonstrate activity enhancement in terms of a better OS or PFS. However, while there was no RECIST response, or CA125 response by GCIG criteria, the PFS in both arms was typical of chemotherapy in PROC. While it is not clear whether every patient was progressing at the time of entry, one could conclude that carboplatin led to SD in both arms and that this had some clinical utility.
It was possible that the increased number of patients requiring dose modification of carboplatin in the PXD arm might have contributed to reduced delivered carboplatin DI or CD, leading to the nonsignificant observed PFS inferiority. As there were no significant differences in DI or CD, platinum delivery was unlikely to be responsible for these observed differences in PFS between the two arms or indeed the failure to demonstrate a significant superiority in the PXD arm.
Weekly scheduling of platinum-based drugs has a significant history. Accelerated weekly cisplatin schedules have demonstrated response rates of 25%-60% in a variety of contexts with sustained survival, especially for combinations with paclitaxel or oral etoposide in PROC [6, 9, 11, [23] [24] [25] [26] [27] [28] . Sharma et al. reported their experience with dose dense carboplatin AUC3 and 70 mg/m 2 paclitaxel weekly and demonstrated a 60% RECIST response rate in platinum-resistant/refractory ovarian cancer with an 8 month median PFS [8] . The authors noted the protective effect of paclitaxel against carboplatin-induced thrombocytopenia, leading to carboplatin dose increase without associated toxicity. Other investigators confirmed that weekly carboplatin and paclitaxel in platinum-refractory disease could achieve response rates ranging from 25% to 60% [10, 11, 28] . A major drawback of this study, however, was that no precedent phase II data exist of assessing the biological and clinical benefits of oral PXD. Regardless, these data do not support further clinical development of oral PXD in human cancer.
The high-priority area of understanding and applying therapeutic strategies that target the mechanisms of acquired platinum resistance in the context of the use of platinum-based chemotherapy in PROC is an undiminished area of unmet need and is complementary and synergistic with other efforts to do the same with nonplatinum chemotherapies. Future research should focus on translating our growing understanding of molecular mechanisms underlying platinum resistance and the identification of tumors that may be responsive to these approaches by better predictive biomarker signatures that may indicate those who would benefit from the reintroduction of platinum in combination with a molecular agent inhibition targeting specific pathways that create platinum resistance.
In conclusion, this phase III study in which PXD was added to weekly AUC2 carboplatin failed to demonstrate an improvement in PFS or OS in a clinically homogenous population of patients with acquired PROC. Results of this study do not negate the strategy to molecularly target platinum resistance in the context of a platinum-based chemotherapy in PROC but at the same time do not support future trials that would propose a fractionated carboplatin backbone as single agent to test reversal of PROC using molecularly targeted agents. 
